JPWO2022016112A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022016112A5 JPWO2022016112A5 JP2023503080A JP2023503080A JPWO2022016112A5 JP WO2022016112 A5 JPWO2022016112 A5 JP WO2022016112A5 JP 2023503080 A JP2023503080 A JP 2023503080A JP 2023503080 A JP2023503080 A JP 2023503080A JP WO2022016112 A5 JPWO2022016112 A5 JP WO2022016112A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- signaling
- costar
- seq
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000011664 signaling Effects 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 10
- 101150013553 CD40 gene Proteins 0.000 claims 9
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102100022464 5'-nucleotidase Human genes 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102100027221 CD81 antigen Human genes 0.000 claims 1
- 102100027217 CD82 antigen Human genes 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- 102000024905 CD99 Human genes 0.000 claims 1
- 108060001253 CD99 Proteins 0.000 claims 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 102100031984 Ephrin type-B receptor 6 Human genes 0.000 claims 1
- 102100035139 Folate receptor alpha Human genes 0.000 claims 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims 1
- 101001064451 Homo sapiens Ephrin type-B receptor 6 Proteins 0.000 claims 1
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 1
- 101000650817 Homo sapiens Semaphorin-4D Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 1
- 102100025304 Integrin beta-1 Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102100039564 Leukosialin Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102100027744 Semaphorin-4D Human genes 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 claims 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 claims 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 claims 1
- 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 claims 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053494P | 2020-07-17 | 2020-07-17 | |
| US63/053,494 | 2020-07-17 | ||
| PCT/US2021/042075 WO2022016112A1 (en) | 2020-07-17 | 2021-07-16 | Receptors providing targeted costimulation for adoptive cell therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023534808A JP2023534808A (ja) | 2023-08-14 |
| JP2023534808A5 JP2023534808A5 (https=) | 2024-07-17 |
| JPWO2022016112A5 true JPWO2022016112A5 (https=) | 2024-07-17 |
Family
ID=77301001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503080A Pending JP2023534808A (ja) | 2020-07-17 | 2021-07-16 | 養子細胞療法のための標的共刺激を提供する受容体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220348631A1 (https=) |
| EP (1) | EP4182338A1 (https=) |
| JP (1) | JP2023534808A (https=) |
| KR (1) | KR20230088333A (https=) |
| CN (1) | CN116348485A (https=) |
| AR (1) | AR123004A1 (https=) |
| AU (1) | AU2021308702A1 (https=) |
| CA (1) | CA3189671A1 (https=) |
| IL (1) | IL299886A (https=) |
| WO (1) | WO2022016112A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
| WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| AU2021308702A1 (en) | 2020-07-17 | 2023-03-16 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
| EP4355340A4 (en) | 2021-06-16 | 2025-05-21 | Instil Bio, Inc. | RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY |
| AR126199A1 (es) * | 2021-06-24 | 2023-09-27 | Instil Bio Inc | Métodos para aislar linfocitos infiltrantes de tumores y uso de los mismos |
| EP4370213A4 (en) | 2021-07-16 | 2025-06-04 | Instil Bio (Uk) Limited | Chimeric molecules for targeted costimulation for adoptive cell therapy |
| AU2023209445A1 (en) * | 2022-01-20 | 2024-08-01 | Instil Bio, Inc. | Receptors providing targeted costimulation for adoptive cell therapy |
| US20240058447A1 (en) * | 2022-05-25 | 2024-02-22 | Instil Bio (Uk) Limited | Use of fusion constructs for il-2 independent t cell therapy |
| EP4565683A1 (en) * | 2022-08-01 | 2025-06-11 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2024243429A2 (en) * | 2023-05-24 | 2024-11-28 | Instil Bio Inc. | Use of fusion constructs for cd4+ t cell therapy |
| CN117947070A (zh) * | 2024-02-01 | 2024-04-30 | 中山大学附属第三医院 | 一种嵌合抗原受体基因及其应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| WO2003008454A2 (en) * | 2001-07-18 | 2003-01-30 | Merck Patent Gmbh | Glycoprotein vi fusion proteins |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| EP3549611B1 (en) | 2011-07-29 | 2021-06-30 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
| AU2013327136A1 (en) | 2012-10-02 | 2015-04-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| SG11201507026WA (en) | 2013-02-06 | 2015-10-29 | Anthrogenesis Corp | Modified t lymphocytes having improved specificity |
| WO2014151960A2 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| US11028143B2 (en) * | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
| MA41538A (fr) | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| US11161907B2 (en) * | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CA2978186A1 (en) | 2015-03-05 | 2016-09-09 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| MX2018005618A (es) * | 2015-11-05 | 2018-08-01 | Juno Therapeutics Inc | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. |
| ES2875747T3 (es) * | 2016-01-11 | 2021-11-11 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia |
| CN109069537B (zh) | 2016-04-04 | 2022-04-15 | 亘喜生物科技（上海）有限公司 | 共刺激结构域中具有重复结合基序的car |
| WO2018156711A1 (en) * | 2017-02-22 | 2018-08-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Il13ra2-binding chimeric antigen receptors |
| AU2018235756B2 (en) | 2017-03-13 | 2024-08-08 | Poseida Therapeutics, Inc. | Compositions and methods for selective elimination and replacement of hematopoietic stem cells |
| AU2018236461B2 (en) | 2017-03-17 | 2025-03-27 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| WO2018200585A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and secondary effectors and uses thereof |
| WO2018208849A1 (en) | 2017-05-09 | 2018-11-15 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
| WO2019067504A1 (en) * | 2017-09-26 | 2019-04-04 | Longwood University | SPECIFIC CHIMERIC ANTIGEN RECEPTOR AT PD-1 AS IMMUNOTHERAPY |
| MA51428A (fr) * | 2017-12-22 | 2020-11-04 | Bluebird Bio Inc | Récepteur d'antigène chimérique multivalent |
| CN112955548B (zh) | 2018-07-09 | 2023-11-24 | 普众发现医药科技(上海)有限公司 | 叶酸受体α特异性抗体 |
| GB201900858D0 (en) | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
| EP4028526A4 (en) | 2019-09-11 | 2023-08-30 | Migal Galilee Research Institute Ltd. | Chimeric antigen receptor comprising cd40 cytoplasmic domain and uses thereof |
| WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| AU2021308702A1 (en) | 2020-07-17 | 2023-03-16 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
| WO2022016114A1 (en) | 2020-07-17 | 2022-01-20 | Instill Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
| EP4355340A4 (en) | 2021-06-16 | 2025-05-21 | Instil Bio, Inc. | RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY |
| AR126199A1 (es) | 2021-06-24 | 2023-09-27 | Instil Bio Inc | Métodos para aislar linfocitos infiltrantes de tumores y uso de los mismos |
| EP4370213A4 (en) | 2021-07-16 | 2025-06-04 | Instil Bio (Uk) Limited | Chimeric molecules for targeted costimulation for adoptive cell therapy |
| US20230227576A1 (en) | 2022-01-20 | 2023-07-20 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
| US20240058447A1 (en) | 2022-05-25 | 2024-02-22 | Instil Bio (Uk) Limited | Use of fusion constructs for il-2 independent t cell therapy |
-
2021
- 2021-07-16 AU AU2021308702A patent/AU2021308702A1/en active Pending
- 2021-07-16 KR KR1020237005387A patent/KR20230088333A/ko active Pending
- 2021-07-16 IL IL299886A patent/IL299886A/en unknown
- 2021-07-16 CA CA3189671A patent/CA3189671A1/en active Pending
- 2021-07-16 CN CN202180062475.1A patent/CN116348485A/zh active Pending
- 2021-07-16 EP EP21752811.6A patent/EP4182338A1/en active Pending
- 2021-07-16 JP JP2023503080A patent/JP2023534808A/ja active Pending
- 2021-07-16 WO PCT/US2021/042075 patent/WO2022016112A1/en not_active Ceased
- 2021-07-19 AR ARP210102020A patent/AR123004A1/es unknown
-
2022
- 2022-06-17 US US17/843,480 patent/US20220348631A1/en active Pending
- 2022-08-30 US US17/823,223 patent/US12187778B2/en active Active